Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[CARD study: relevance for the treatment of advanced prostate cancer].
Merseburger AS, Bannowsky A, Becker K, Bokemeyer C, Eichenauer R, Lehmann J, Mickisch G, Steuber T, von Amsberg G, von Kügelgen T, Wülfing C. Merseburger AS, et al. Among authors: lehmann j. Aktuelle Urol. 2022 Feb;53(1):54-59. doi: 10.1055/a-1247-4155. Epub 2020 Sep 23. Aktuelle Urol. 2022. PMID: 32968994 Clinical Trial. German.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Smith MR, et al. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Free article. Clinical Trial.
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE. Retz M, et al. Among authors: lehmann j. Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529901 Clinical Trial.
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.
Heinzelbecker J, Spieler N, Kuehn M, Fischer C, Volkmer B, von Rundstedt F, Albers P, Becht E, Bannowsky A, Weber HM, Hofmann R, Müller M, Langbein S, Steiner G, Retz M, Kamradt J, Wagenpfeil G, Wellek S, Lehmann J, Stoeckle M. Heinzelbecker J, et al. Among authors: lehmann j. Urol Oncol. 2023 Aug;41(8):356.e19-356.e30. doi: 10.1016/j.urolonc.2023.04.016. Epub 2023 May 16. Urol Oncol. 2023. PMID: 37198025 Clinical Trial.
[Gemcitabine in advanced bladder cancer].
Lehmann J, Retz M, Lippert C, Albers P, Stöckle M. Lehmann J, et al. Urologe A. 2003 Jan;42(1):63-77. doi: 10.1007/s00120-002-0222-2. Epub 2002 Dec 19. Urologe A. 2003. PMID: 12574885 Review. German.
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).
Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M. Lehmann J, et al. Eur Urol. 2009 Jun;55(6):1293-9. doi: 10.1016/j.eururo.2008.11.039. Epub 2008 Nov 29. Eur Urol. 2009. PMID: 19058907
[Complete resection of urothelial cancer metastases with curative intent].
Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M. Lehmann J, et al. Urologe A. 2009 Feb;48(2):143-50. doi: 10.1007/s00120-008-1901-4. Urologe A. 2009. PMID: 19142626 Clinical Trial. German.
[Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].
Hartmann M, Siener R, Krege S, Schmelz H, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Albers P; German Testicular Cancer Study Group. Hartmann M, et al. Among authors: lehmann j. Urologe A. 2009 May;48(5):523-8. doi: 10.1007/s00120-008-1927-7. Urologe A. 2009. PMID: 19183929 Clinical Trial. German.
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M. Lehmann J, et al. Urologe A. 2003 Aug;42(8):1074-86. doi: 10.1007/s00120-003-0317-4. Epub 2003 Apr 2. Urologe A. 2003. PMID: 14513232 Clinical Trial. German.
1,503 results